FR3071150A1 - FIBRINOGEN-THROMBIN BIOREACTOR - Google Patents

FIBRINOGEN-THROMBIN BIOREACTOR Download PDF

Info

Publication number
FR3071150A1
FR3071150A1 FR1770973A FR1770973A FR3071150A1 FR 3071150 A1 FR3071150 A1 FR 3071150A1 FR 1770973 A FR1770973 A FR 1770973A FR 1770973 A FR1770973 A FR 1770973A FR 3071150 A1 FR3071150 A1 FR 3071150A1
Authority
FR
France
Prior art keywords
fibrinogen
thrombin
bioreactor
blood
fibrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR1770973A
Other languages
French (fr)
Inventor
Francois Forestier
Steve Eisenhut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1770973A priority Critical patent/FR3071150A1/en
Priority to FR1870304A priority patent/FR3071151A1/en
Publication of FR3071150A1 publication Critical patent/FR3071150A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47—Sanitary towels, incontinence pads or napkins
    • A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Le sang des règles contenant de la prothrombine, mais aussi tous les autres facteurs de la coagulation à l'exception du fibrinogène, est incoagulable. L'activation de la voie endogène par la mise en jeu des facteurs contact doit être suffisante pour transformer la prothrombine en thrombine agissant ainsi sur le fibrinogène (composant ajouté au sein du bioréacteur) pour le transformer en fibrine. Il est légitime de penser que la quantité de thrombine générée soit suffisante pour engendrer la coagulation du sang, mais on peut imaginer un ajout supplémentaire de thrombine (au sein du bioréacteur) qui jouerait un rôle catalytique supplémentaire. Le protocole opératoire consiste à rajouter du fibrinogène à une concentration de l'ordre de 1 gramme par litre (de sang) et de la thrombine à environ 10 UI (Unités internationales) par litre pour activer la transformation du fibrinogène en fibrine.The blood of the menses containing prothrombin, but also all the other factors of coagulation except fibrinogen, is incoagulable. Activation of the endogenous pathway through contact factors must be sufficient to convert prothrombin to thrombin, thereby acting on fibrinogen (a component added within the bioreactor) to transform it into fibrin. It is legitimate to think that the amount of thrombin generated is sufficient to cause blood coagulation, but one can imagine an additional addition of thrombin (within the bioreactor) that would play an additional catalytic role. The operating procedure consists of adding fibrinogen at a concentration of the order of 1 gram per liter (of blood) and thrombin to about 10 IU (International Units) per liter to activate the conversion of fibrinogen to fibrin.

Description

Objectif du document L'objectif de ce document est de décrire une demande de brevet concernant un Bioréacteur Fibrinogène-Thrombine. Ce bioréacteur a comme rôle de permettre la coagulation du sang des règles des femmes. Le brevet doit porter sur la procédure qui permet le processus de coagulation du sang des règles.Purpose of the Document The purpose of this document is to describe a patent application for a Fibrinogen-Thrombin Bioreactor. This bioreactor's role is to allow blood clotting of the rules of women. The patent must relate to the procedure that allows the process of blood clotting rules.

Personnes impliquéesInvolved persons

Dans le cadre de cette demande de brevet, les personnes impliquées ont les statuts suivants : • Inventeur : Professeur François Forestier • Co Inventeur : Steve EisenhutIn the context of this patent application, the persons involved have the following status: • Inventor: Professor François Forestier • Inventor Co: Steve Eisenhut

Description de l’objet de la demande de brevetDescription of the subject of the patent application

Dans le cadre d'un tampon hygiénique innovant, il nous est apparu évident qu'on pouvait mettre à profit des connaissances au sujet de la coagulation pour concevoir un nouveau dispositif sur la base d'un bioréacteur.In the context of an innovative hygienic tampon, it became clear to us that knowledge about coagulation could be used to design a new device based on a bioreactor.

Dans ce contexte, le bioréacteur offre la possibilité qu'ont des substances de transformer un milieu liquide en un milieu gélifié. Concernant la coagulation du sang des règles, cette transformation sol-gel est due à la thrombine qui transforme une molécule soluble (le fibrinogène) en molécule insoluble (la fibrine).In this context, the bioreactor offers the possibility of substances transforming a liquid medium into a gelled medium. Concerning the blood coagulation of the rules, this sol-gel transformation is due to thrombin which transforms a soluble molecule (fibrinogen) into an insoluble molecule (fibrin).

Plus précisément, au sein de cette demande de brevet, notre bioréacteur est un ensemble biologique constitué d'un substrat (fibrinogène) et d'une enzyme (thrombine) permettant la transformation d'un milieu biologique (le sang des règles dans notre cas) d'un état à un autre (notamment sol-gel).More specifically, within this patent application, our bioreactor is a biological set consisting of a substrate (fibrinogen) and an enzyme (thrombin) for the transformation of a biological medium (the blood of the rules in our case) from one state to another (especially sol-gel).

Le sang des règles a effectivement comme particularité de ne pas contenir du fibrinogène. C'est pourquoi notre dispositif contient une protéine (le fibrinogène) et une enzyme (la thrombine). Dès lors notre dispositif, intégré au sein même du concept développé dans le nouveau brevet « Tampon Hygiénique 2.0 », permet une protection des menstruations totalement nouvelle puisque cette nouveauté intègre deux brevets, celui d'une structure totalement innovante, et la possibilité pour la première fois de rendre ce sang coagulable, améliorant ainsi le confort des protections féminines au court des menstruations.The blood of rulers actually has the peculiarity of not containing fibrinogen. This is why our device contains a protein (fibrinogen) and an enzyme (thrombin). Therefore our device, integrated within the concept developed in the new patent "Tampon Hygienic 2.0", allows a completely new menstruation protection since this novelty includes two patents, that of a completely innovative structure, and the possibility for the first time. to make this blood coagulable, thus improving the comfort of feminine protection during menstruation.

Le sang des règles contenant de la prothrombine, mais aussi tous les autres facteurs de la coagulation à l'exception du fibrinogène, est incoagulable. L'activation de la voie endogène par la mise en jeu des facteurs contact doit être suffisante pour transformer la prothrombine en thrombine agissant ainsi sur le fibrinogène (composant ajouté au sein du bioréacteur) pour le transformer en fibrine. Il est légitime de penser que la quantité de thrombine générée soit suffisante pour engendrer la coagulation du sang, mais on peut imaginer un ajout supplémentaire de thrombine (au sein du bioréacteur) qui jouerait un rôle catalytique supplémentaire. Le protocole opératoire consiste à rajouter du fibrinogène à une concentration de l'ordre de 1 gramme par litre (de sang) et de la thrombine à environ 10 Ul (Unités Internationales) par litre pour activer la transformation du fibrinogène en fibrine.The blood of the menses containing prothrombin, but also all the other factors of coagulation except fibrinogen, is incoagulable. Activation of the endogenous pathway through contact factors must be sufficient to convert prothrombin to thrombin, thereby acting on fibrinogen (a component added within the bioreactor) to transform it into fibrin. It is legitimate to think that the amount of thrombin generated is sufficient to cause blood coagulation, but one can imagine an additional addition of thrombin (within the bioreactor) that would play an additional catalytic role. The operating procedure consists of adding fibrinogen at a concentration of the order of 1 gram per liter (of blood) and thrombin to about 10 IU (International Units) per liter to activate the conversion of fibrinogen to fibrin.

Claims (1)

Original document published without claims.Original document published without claims.
FR1770973A 2017-09-16 2017-09-16 FIBRINOGEN-THROMBIN BIOREACTOR Pending FR3071150A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1770973A FR3071150A1 (en) 2017-09-16 2017-09-16 FIBRINOGEN-THROMBIN BIOREACTOR
FR1870304A FR3071151A1 (en) 2017-09-16 2018-03-17 FIBRINOGEN-THROMBINE BIOREACTOR THAT TRANSFORMS BLOOD OF THE RULES OF WOMEN IN GEL

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1770973A FR3071150A1 (en) 2017-09-16 2017-09-16 FIBRINOGEN-THROMBIN BIOREACTOR

Publications (1)

Publication Number Publication Date
FR3071150A1 true FR3071150A1 (en) 2019-03-22

Family

ID=63579498

Family Applications (2)

Application Number Title Priority Date Filing Date
FR1770973A Pending FR3071150A1 (en) 2017-09-16 2017-09-16 FIBRINOGEN-THROMBIN BIOREACTOR
FR1870304A Withdrawn FR3071151A1 (en) 2017-09-16 2018-03-17 FIBRINOGEN-THROMBINE BIOREACTOR THAT TRANSFORMS BLOOD OF THE RULES OF WOMEN IN GEL

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR1870304A Withdrawn FR3071151A1 (en) 2017-09-16 2018-03-17 FIBRINOGEN-THROMBINE BIOREACTOR THAT TRANSFORMS BLOOD OF THE RULES OF WOMEN IN GEL

Country Status (1)

Country Link
FR (2) FR3071150A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2033046C (en) * 1990-01-12 1999-08-03 Lowell Saferstein Process for preparing a neutralized oxidized cellulose product and its method of use
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids

Also Published As

Publication number Publication date
FR3071151A1 (en) 2019-03-22

Similar Documents

Publication Publication Date Title
Gragnano et al. The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy
Kamphuisen et al. Elevated factor VIII levels and the risk of thrombosis
Weitz et al. Periprocedural management and approach to bleeding in patients taking dabigatran
Intengan et al. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition
Lambourne et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate
Fakhouri Pregnancy-related thrombotic microangiopathies: clues from complement biology
Cleland et al. Massive haemorrhage in liver transplantation: Consequences, prediction and management
Acharya et al. Rare inherited disorders of fibrinogen
Sandfeldt et al. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride
Tran et al. Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction
Armas-Padilla et al. Nitric oxide and malondialdehyde in human hypertension
Tabue-Teguo et al. Frailty in elderly: a brief review
Majumdar et al. In vivo anticoagulant and thrombolytic activities of a fibrinolytic serine protease (Brevithrombolase) with the k-carrageenan-induced rat tail thrombosis model
Swamy Blood transfusion practices in liver transplantation
Gregory et al. The perioperative management of ascending aortic dissection
Uhlmann et al. Recombinant activated factor VII for non-hemophiliac bleeding patients
Gómez-Moreno et al. Hereditary blood coagulation disorders: management and dental treatment
FR3071150A1 (en) FIBRINOGEN-THROMBIN BIOREACTOR
Pierre et al. Blockade and reversal of endothelin-induced constriction in pial arteries from human brain
Karkouti et al. Recombinant activated factor VII: the controversial conundrum regarding its off-label use
Henneton et al. Arterial fragility in kyphoscoliotic Ehlers-Danlos syndrome
Girolami et al. Bleeding manifestations in heterozygotes with prothrombin deficiency or abnormalities vs. unaffected family members as observed during a long follow-up study
Olsen et al. Can preoperative sex-related differences in hemostatic parameters predict bleeding in orthognathic surgery?
Niemann et al. Role of spleen and liver for enhanced hemostatic competence following administration of adrenaline to humans
Valke et al. Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment.